evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,181 questions · 1,197 findings · 144 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 196 · 16.4%GRADE not reported 213 · 17.8%Very low 274 · 22.9%Low 296 · 24.7%Moderate 171 · 14.3%High 47 · 3.9%

Ketogenic diet (KD) vs usual care

Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy

It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

50% or greater reduction in seizure frequency · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Treatment withdrawal for any reason Duration of treatment (range): 12 (3 months) to 36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes treatment withdrawal for any reason Duration of treatment (range):… compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Ataxia · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: ataxia Duration of treatment (range): 7–36 weeks compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: dizziness, lightheadedness · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: dizziness/light‐headedness Duration of treatment… compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effect: fatigue · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin may leads to higher adverse effects: fatigue Duration of treatment (range): 8–36 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).

1 finding from 1 review

Vigabatrin vs placebo

Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).

1 finding from 1 review